Addition Therapeutics
South San Francisco
About Addition Therapeutics
Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovative methods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $100.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: additiontx.com
- Phone: +1 650 395 7899
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/addition-therapeutics-11041 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.